LEGN (Legend Biotech) Scaled Net Operating Assets: 0.30 (As of Mar. 2026)


LEGN Legend Biotech Corp LEGN
73 GF Score
Price $28.70
GF Value $98.55
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Legend Biotech Scaled Net Operating Assets?

Legend Biotech LEGN +0.91% 73 Scaled Net Operating Assets is 0.30 as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 73/100 and a GF Value™ of $98.55 (Possible Value Trap). The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Legend Biotech's operating assets for the quarter that ended in Mar. 2026 was $762 Mil. Legend Biotech's operating liabilities for the quarter that ended in Mar. 2026 was $240 Mil. Legend Biotech's Total Assets for the quarter that ended in Dec. 2025 was $1,734 Mil. Therefore, Legend Biotech's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.30.


Legend Biotech Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Scaled Net Operating Assets Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.01 0.00 0.20 0.15 0.28

Legend Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.28 0.25 0.27 0.30

LEGN vs DNTH, XENE, CAI: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Legend Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Legend Biotech Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Legend Biotech's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Legend Biotech's Scaled Net Operating Assets falls into.


LEGN
73GF Score
Legend Biotech Corp LEGN
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Legend Biotech's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(785.1-317.9)/1670.2
=0.28

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1733.7 - 948.6
=785.1

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=731.6 - 87.2 - 326.5
=317.9

Legend Biotech's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(762.1-239.7)/1733.7
=0.30

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1596.7 - 834.6
=762.1

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=629 - 112.1 - 277.2
=239.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.30 mean?
Legend Biotech (LEGN) has a Scaled Net Operating Assets of 0.30 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Scaled Net Operating Assets too high?
Legend Biotech's current Scaled Net Operating Assets is 0.30. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Scaled Net Operating Assets compare to DNTH and XENE?
Legend Biotech's Scaled Net Operating Assets of 0.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Legend Biotech and its competitors. Legend Biotech's current Scaled Net Operating Assets is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $98.55, compared to a current price of $28.70 — trading 70.9% below its estimated fair value. The current Scaled Net Operating Assets is 0.30. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Scaled Net Operating Assets is 0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $28.70 is trading 70.9% below its estimated GF Value™ of $98.55. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Scaled Net Operating Assets: 0.30
  • GF Value™: $98.55 vs. price of $28.70 (70.9% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score

Get the complete analysis for LEGN

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.70
Price
$98.55
GF Value